[Adverse reactions to carcinostatics and countermeasures].
As adverse reactions to the combination treatment by the digestive system, we observed the occurrence of nausea and vomiting in 15% of the cases who received FTP treatment consisting of 5-FU, toyomicin and prednisone, 25% of the cases who received MFU treatment consisting of MMC, 5-FU and ACNU, and in 64% of the cases who received PPQ treatment consisting of CDDP, Carboquone (CQ) and prednisone. The antiemetics usually used are metoclopramide and droperidol, and we preadminister valproate preparation when persistent and delayed emesis is predicted. Several randomized trials have been made, and good efficacies with drugs such as metoclopramide, domperidone and steroid have been reported. Efficacy was good with acute emesis, but nonexistent with delayed emesis. As to the liver injury, in our combination treatment, only one case showed elevation of GPT by more than 500 units in the cases treated with MFU, while, increase in liver enzymes in the blood was observed in 10-20% of the cases. Similarly, there were not so many cases of liver injury during PPQ treatment. Thus, liver injury due to carcinostatic would be less frequent. Moreover, autopsy revealed hepatocellular-type of liver injury, cholestatic type liver injury and fatty metamorphosis at reasonable incidence. There were no typical cases of veno-occlusive disease which are noticed recently. The most important point for prevention and countermeasures against liver injury is to be careful not to use the previously mentioned drugs exhibiting toxicity in the liver if hepatic disease exists.
Nakao
I
I
Dept. of Internal Medicine, Cancer Institute Hospital, Tokyo.
D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002225:Carbazilquinone / Q000008:administration & dosage; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000517:prevention & control; D014128:Chromomycin A3 / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008099:Liver / Q000187:drug effects; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy; D015376:Nimustine / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy
D000932:Antiemetics; D008937:Mitomycins; D009944:Organoplatinum Compounds; D015376:Nimustine; D002225:Carbazilquinone; C055423:didimethylsulfoxide dichloroplatinum(II); D016685:Mitomycin; D014128:Chromomycin A3; D005472:Fluorouracil; D011241:Prednisone